AUPH Aurinia Pharmaceuticals
Aurinia Pharmaceuticals earnings company data as of 7:49 PM ET 10/23
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 3 Nov | EPS | 0.18 | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by AUPH's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $25.1M bought by 1 insider
- None no sales outside a trading plan
- None no planned (10b5-1) sales
-
Kevin Tang CEO, +1 joint filerBuy$12.5M 814,606 shares at $15.29 +6.7% to stakeTraded May 29–Jun 2 Filed Jun 2
-
Kevin Tang DirectorBuy$12.7M 900,000 shares at $14.10 +7.9% to stakeTraded Feb 27–Mar 3 Filed Mar 3
Also filed in the last 12 months, not counted as buying or selling: 16 share withholdings for taxes, 12 stock grants, and 2 sales to cover taxes.
SEC filings
Recent issuer filings from EDGAR, 16 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| SCHEDULE 13D/A | — | Filing Doc | |
| 8-K | 8.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13D/A | — | Filing Doc | |
| 8-K | 5.07,9.01 | Filing Doc | |
| 8-K | 2.01,9.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| DEF 14A | Filing Doc | ||
| 8-K | 1.01,7.01,9.01 | Filing Doc | |
| SCHEDULE 13D/A | — | Filing Doc | |
| 8-K | 5.02,9.01 | Filing Doc | |
| SCHEDULE 13D/A | — | Filing Doc | |
| 8-K | 2.02 | Filing Doc | |
| 10-K | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.